Latest Commercial Expansion News

Page 8 of 19
Insignia Financial Limited will be removed from the S&P/ASX 200 Index ahead of its acquisition by Daintree BidCo, with 4DMedical Limited stepping in on April 20, 2026.
Claire Turing
Claire Turing
13 Apr 2026
Memphasys Limited (ASX: MEM) announced an investor webinar and released an updated presentation detailing its transition from early-stage commercialisation to scaling global revenues, highlighting multi-market sales, recurring cartridge revenue, and regulatory progress.
Ada Torres
Ada Torres
7 Apr 2026
Nexsen Limited (ASX:NXN) has completed its Stage 1 ISO 13485 audit, confirming its Quality Management System (QMS) supports clinical validation and regulatory submissions for its diagnostic products, including StrepSure®. The company is progressing toward full certification and alignment with MDSAP requirements to facilitate global market access.
Ada Torres
Ada Torres
7 Apr 2026
Imricor Medical Systems has filed a Form 10 registration with the U.S. SEC, marking its transition to a U.S. reporting company amid ongoing FDA clearances and clinical trials. This move signals a significant step in its early commercialisation of MRI-guided cardiac ablation technology.
Ada Torres
Ada Torres
19 Mar 2026
TZ Limited has completed a A$1.5 million capital raise at a premium, appointed David Sampaklis as Group CEO with significant shareholding, and repaid A$1 million of debt, positioning itself for growth in data centre security.
Sophie Babbage
Sophie Babbage
12 Mar 2026
Straker Ltd announces a pivotal leadership shift with the appointment of David Sowerby and Indiver Nagpal as Co-CEOs, marking a new era focused on commercial expansion and AI innovation. Founder Grant Straker transitions to a strategic board role to steer the company’s AI future.
Sophie Babbage
Sophie Babbage
4 Mar 2026
Yojee Limited reported a 9% revenue increase driven by software activities, while net losses widened due to accelerated investment in its MOSAIC platform and joint venture costs. The company maintains a robust cash balance and has strengthened its leadership ahead of a mid-2026 commercial launch.
Sophie Babbage
Sophie Babbage
27 Feb 2026
4DMedical Limited’s half-year report reveals rapid commercial traction following FDA clearance of its CT:VQ™ imaging technology, alongside a $150 million institutional placement that bolsters its cash reserves for global expansion.
Ada Torres
Ada Torres
27 Feb 2026
ReNerve Limited reported a half-year loss of $2.72 million, up 47% from last year, as it expands its nerve repair product portfolio and secures new regulatory approvals in Asia-Pacific.
Ada Torres
Ada Torres
26 Feb 2026
First Graphene Limited reported a strong 53% revenue increase driven by new industrial applications, yet posted a $3.35 million net loss influenced by non-cash finance costs. The company’s recent $3.5 million capital raise positions it to focus on commercial expansion without further funding.
Maxwell Dee
Maxwell Dee
25 Feb 2026
Immuron Limited reported a narrower half-year loss alongside record sales growth and FDA approval for its IMM-529 drug candidate, signalling promising clinical and commercial momentum.
Ada Torres
Ada Torres
25 Feb 2026
Imricor Medical Systems saw a sharp 69.5% decline in revenue for 2025, driven by clinical trial impacts, yet narrowed its net loss to $25.3 million as it secured FDA clearance for key products post-year-end.
Ada Torres
Ada Torres
25 Feb 2026

Browse the archive

Full archive